DOCSLIB.ORG

Inhibition of C-MYC Expression Through Disruption of an RNA*Protein Interaction Using Antisense Oligonucleotides

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inhibition of C-MYC Expression Through Disruption of an RNA*Protein Interaction Using Antisense Oligonucleotides inhibition of c-MYC Expression Through Disruption of an RNA*Protein interaction Using Antisense Oligonucleotides Christopher M. Coulis A thesis submitted in coafodty with the requirements for the degree of Master of Science Graduate Department of Pharmacology University of Toronto Q Copyright by Chnstopher M. Coulis 1999 National Libraiy Bibliothèque nationale l*l of,", du Canada Acquisitions and Acquisitions et Bibliographie Services services bibliographiques 395 Wellington Street 395. rue Weilington OttawaON KlAW O(tawaON KlAûN4 Canada Canada The author has granted a non- L'auteur a accordé une licence non exclusive Licence allowing the exclusive permettant à la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or sell reproduire, prêter, distri'buer ou copies of this thesis in microform, vendre des copies de cetîe thèse sous paper or electronic formats. la fome de microfiche/film, de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts firom it Ni la thèse ni des extraits substantiels may be printed or othenvise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. ABSTRACT The proto-oncogene c-myc encodes a protein that regdates cellular proliferation and differentiation. Conditions that alter the stability of c-myc mRNA can lead to overexpression of the gene resulting in uncontrolled cell growth. Synthetic therapeutic agents, known as Antisense Oligonucleotides (ODN), cm bind to target mRNA and inhibit its expression. A previously characterized protein, the coding region stability determinam-binding protein (CRD-BP),binds the coding region deteminant (CRD)of c-myc mRNA and is believed to protect it fmm endonucleolytic cleavage. Accordingly, we hypothesized that ODNs directed towards the CRD of c-m_vc mRNA could prevent CRD-BP*RNA interactions, thus decreasing c-myc expression. Using an in vitro gel shift assay we demonstrated that ODNs inhibit the CRD-BP*c-nryc mRNA interaction. The most effective ODN, CRD-ODN4, exhibited a sequence-specific and concentration-dependent inhibition of the RNA*CRD-BP interaction, with a maximal inhibition of 75% at 1 FM. K562 cells treated with a 2'-O-methyl derivative of CRD-0DN4 displayed a concentration4ependent decrease of c-myc expression. Up to 65% inhibition of protein expression and 45% inhibition of mRNA expression was observed with 200 nM of CRD-ODN4- Conversely, a 2'-O-methyl ODN derivative targeting the translational initiation codon (ODN- AUG) reduced c-myc protein but increased mRNA levels 2-fold. The effect of ODN-AUG was partially due to increased mRNA stability. ODN-AUG treatment increased the haii-life of c-myc mRNA from 30 min to 70 min whereas the half-life of c-myc mRNA after treatment with CRD- 0DN4 was not signif~wntlydifferent from the control. Additionally, CRD-0DN4 was more effective at inhibiting K562 ce11 growth, reducing ce11 number by - 7Wo after 48 h of exposure to 750 UMODN. The results observed both in vin0 and within cells support the hypothesis that CRD-ODN4 is capable of disrupting the interaction between CRD-BPand c-myc mRNA and this disruption decreases c-myc expression and functional effects in cells. 1 would like to than my supervisor, Dr. Rebecca Rokipcak for giving me the opportwity to do pduate work in her iaboratory, and for her invaluable support, encouragement and advice. 1 would like to offer special thanks to Leonardo Salmena and Vienthong Lam for their tutorials in Western Blot and MIT assays and for their helpful discussions and support. I also offer spetial thanks to Christine Albino for her support and discussions. Finally, 1 wish to thank my mother, whose continued support, understanding and patience made everything possible. 1 couidn't have doue it without any of these parties, and to al1 of you 1 dedicate this thesis. iii TABLE OF CONTENTS .. ABSTRACT 11 .-- ACKNOWLEDGEME:NTS 111 TABLE OF CONTENTS iv LIST OF TABLES vii LIST OF F'IGURES vü LIST OF ABBREVIATIONS ix 1. INTRODUCTION 1.1 Antisense Oiigonticleotides Bac kground OLigonucleotide Structural Modikations Oligonucleotide Afinity and Specifici ty Uptake and Distribution of Oligonucleotides Antisense OligonucIeotide Mechanisms of Action Antisense Oligonucteotide Toxicity Antisense Oligonucleotides in Cancer Chemotherapy 1.2 Proto-oncogenec-myc 1.2.1 Background 1.2.2 Structures of c-myc Gene and Protein 1.23 Mechanisms of Myc Regulation 1.2.4 Activation of Gene Expression by Mye 13 Myc as a Target of ODN Therapy 1.4 Ratiode for Ciiri~ntStrdy 1 -4.1 Preliminary Data 14.2 ffypothesis II. MATERIALS AND METHODS So-e of Materials Cell Line Oligonucleotide Preparation Probe Preparation for Northem Analysis Labeling DNA Probe Probe Pre paration for Ribonuclease Protection Assay Treatment of ceb with Antisense Oligonacleotides Transfection of ODN into Cells Expression of c-myc mRNA and Protein in K562 CeUs RNA Isolation RNA Eiectrophoresis and Northem Transfer Northern Hybridization Analysis Ri bonuclease Protection Assay Protein Isolation Protein Electrophoresis and Western Blot Analysis Estimation of c-myc mRNA =Life Aatisense Oligonncleotide Effect on CeU Gmwth MTT Growth Assay v 3.1 Assay Opthization Range of Detection for c-myc by Western Blot Analysis and RNase Protection Assay Carrier Molecule Selection K562 Exposure Time to ODN fffect of Superfect on K562 Cell Growth 3.2 Effeetg of CRD Airtisense Oiyonocieotides on c-nryc mRNA and Protein Levels in K562 Ceûs c-myc mRNA Levels c-myc Protein Levels Cornparison of 2'OM Versus PS Dose-Dependent Inhibition of c-myc Expression 33 Cornparison of the Effect of 0DN4 and ODN-AUG on c-myc mRNA Stability 3.4 Effect of 0DN4 and ODN-AUGon K562 Ceiï Proliferstion IV. DISCUSSION V. FUTURE DIRECTIONS VI. REFERENCES LIST OF TABLES Table 1. Examples of inhibition of Malignant Cell Growth in vino and in Animal Models by ODNs Table 2. ODN Sequences Used in Sudy vii LIST OF FIGURES Figum 1. Structure and Sites of Chemical Modifications Made to 5 Phosphdester Oligonucleotides Figure 2. Human c-myc Gene and Structural Domains of c-myc Protein 19 Fwre 3. Schematic Representation of Human c-myc mRNA 23 Figure 4. Pathways of Transcriptional Activation or Repression by c-myc 28 Fire5. Schematic Representation of Roposed ODN Mechanism of Action 3 1 Fiire 6. Gel- Shift Analysis of a Panel of ODNs Targeting the CRD of c-myc mRNA Figure 7. Optirnizatioa of RNase Protection and Western Blot Anal ysis Fii8. Comparison of Carrier MoIecules Figure 9. Optimization of ODN Treatment The Figure 10. Superfect Dose-response Curve Foire11. Effects of ODNs on c-myc mRNA Levels in Cells Fiire 12. Effects of ODNs on c-mye Rotein Levels in Cells Fire 13. Comparison of 0DN4 as Both a PS and 2'OM Derivative Figure 14. Concentration-dependent Effect of 0DN4 and ODN-AUG on c-myc mRNA Levels Figure 15. Concentration-dependent Effect of 0DN4 and ODN-AUG on c-myc Protein Levels Fignre 16. c-rnyc mRNA Decay Rate Following Treatment with ODN4 or ODN-AUG Figure 17. Effect of ODN4 and ODN-AUG on K562 Ce11 Growth viii 2'OM - 2'-O-methylribose Oiigonucleotide 3 '-UTR - 3'-untranslated region 4G - G-quartet 5'-UTR - 5'-untraasIated region A - Acidic region A, - absorbance at 260 nm ARE - Adenylateturidylate rich element AU - Adenylatehridylate AUG - initiation codon B - Basic regon bp - base pair cDNA - Complementary DNA reverse transcribed from RNA CML - Chronic myeloid leukemia CO, - Carbon dioxide CpG - Cytosine/Guanine residues flanked by two purines on 5'-end and two pnrnidines on 3'-end cpm - Counts per mitlion CRD - Coding region determinant CRDBP - Coding region stability determinant binding protein C-terminal - Carboxy terminal CUG - Initiation codon BSA - Bovine serum albumin dATP - Deoxyadenosine 5' triphosphate dCrP - Deoxycytidine 5' triphosphate ddH20 - Double distiiled water DEPC - Diethylpyrocarbonate DMSO - Dimethylsulfoxide DNA - DeoxyribonucIeic acid dNTPs - Deoxynucleotide triphosphates DRB - 56-dicloro-1-beta-D-~bofuranosylbenWmidazole d?TP - Deoxythymidine 5' triphosphate DTT - Dithiothreitol E-box - Enhancer box ECL - cherniluminescence detection system EDTA - Ethylenediamine tetracetic acid FBS - Fetal bovine serum GAPDH - Glyceraîdehyde-3-phosphate dehydrogenase GC - GiianinefCytosine HBV - Hepati tis B virus HCl - Hydrochloric acid Hepes-KOH - Hepesfpotassium hydroxide HIV - Human irnmunodeficiency Mnis HLH - Helix loop helix hrs - hours ix K562 - humau erythroleukemia cell line k, - Speed of association kb - Kilobase kDa - Kilodalton KH - Region of homology to RNA-binding domain of ribonucleoprotein K L - litre LZ - Leucine Ppper M - Molar mg - Miilignun grams) mins - minutes mg - Milli gram ( 1U3 grams) ml - Millilitre ( litres) mM - Millimolar ( 10'~ molar) MOPS - 3-fN-Morpholino] pmpanesulfonic acid mRNA - Messenger RNA MIT - 3-[4~dimeihylthiazol-2-yl]-2~diphenyltbromide NaCl - Sodium chloride NaH,PO, - Sodium phosphate ng - Nanogram (109grams) NLS - Nuclear localization signal nM - Nanomolar (l~-~molar) nt - Nucleotide N-terminal - Amino terminal ODN - Antisense Oligonucleotides OLB - Oligo labeling buffer PBS - Phosphate buffered saline PCR - Polymerase chah reaction PO - Phosphodiester Oligonucleotide PS - Phosphorothioate Oligonucleotide RGG - Arginine/guanine/guanine RNA - Ribonucleic acid RNase H - Ribonuclease H RNase L - Ribonuclease L RRM - RNA recognition
Load more

Recommended publications
  • ©Ferrata Storti Foundation
    original paper Haematologica 1997; 82:395-401 HUMAN LEUKEMIA K562 CELLS: INDUCTION TO ERYTHROID DIFFERENTIATION BY GUANINE, GUANOSINE AND GUANINE NUCLEOTIDES FABIO OSTI,* FEDERICA GINANNI CORRADINI,* STEFANIA HANAU,* MAURIZIO MATTEUZZI,* ROBERTO GAMBARI*° *Department of Biochemistry and Molecular Biology; °Biotechnology Center, University of Ferrara; Italy ABSTRACT Background and Objective. Human leukemic guanine, guanosine and guanine ribonucleotides K562 cells are able to undergo erythroid differenti- are effective inducers of K562 cell differentiation. ation in vitro when cultured with a variety of induc- Expression of both Hb Portland and Hb Gower 1 is ers, leading to increased expression of embryo-fetal increased in GTP-induced K562 cells. This increase globin genes such as the ␨, ⑀ and ␥-globin genes. is associated with greater ␥-globin mRNA accumu- Therefore the K562 cell line has been proposed as a lation. By contrast, ATP, CTP and UTP are not able very useful in vitro model system for determining the to induce erythroid differentiation. therapeutical potential of new differentiating com- Interpretaton and Conclusions. These findings sug- pounds as well as for studying the molecular mech- gest that guanine, guanosine and guanine ribonu- anism(s) that regulate changes in the expression of cleotides are inducers of erythroid differentiation of embryonic and fetal human globin genes. In this K562 cells. This is of some relevance since differen- study we explored whether nucleoside triphos- tiating compounds have been proposed as antitu- phates and related compounds are able to induce mor agents. In addition, inducers of erythroid dif- ferentiation that stimulate ␥-globin synthesis might differentiation of K562 cells. Methods. be considered in the experimental therapy of hema- K562 cell differentiation was studied tological diseases associated with a failure in the using the benzidine test; hemoglobins were charac- expression of adult ␤-globin genes.
    [Show full text]
  • Profiling of Metabolic Differences Between Hematopoietic Stem Cells
    H OH metabolites OH Article Profiling of Metabolic Differences between Hematopoietic Stem Cells and Acute/Chronic Myeloid Leukemia 1, 2, 1, 1 1 Byung Hoo Song y, Su Young Son y, Hyun Kyu Kim y, Tae Won Ha , Jeong Suk Im , Aeli Ryu 3, Hyeji Jeon 3, Hee Yong Chung 4, Jae Sang Oh 5,* , Choong Hwan Lee 2,6,* and Man Ryul Lee 1,* 1 Soonchunhyang Institute of Medi-Bio Science (SIMS), Soon Chun Hyang University, Cheonan 31151, Korea; [email protected] (B.H.S.); [email protected] (H.K.K.); [email protected] (T.W.H.); [email protected] (J.S.I.) 2 Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Korea; [email protected] 3 Department of Obstetrics and Gynecology, Soonchunhyang University Cheonan Hospital, Chungcheongnam-do 31151, Korea; [email protected] (A.R.); [email protected] (H.J.) 4 Department of Microbiology, College of Medicine and Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea; [email protected] 5 Department of Neurosurgery, College of Medicine, Soonchunhyang University, Cheonan Hospital, Cheonan 31151, Korea 6 Research Institute for Bioactive-Metabolome Network, Konkuk University, Seoul 05029, Korea * Correspondence: [email protected] (J.S.O.); [email protected] (C.H.L.); [email protected] (M.R.L.); Tel.: +82-10-2918-3903 (J.S.O.); +82-2-2049-6177 (C.H.L.); +82-41-413-5013 (M.R.L.) These authors equally contributed to this work. y Received: 29 September 2020; Accepted: 22 October 2020; Published: 26 October 2020 Abstract: Although many studies have been conducted on leukemia, only a few have analyzed the metabolomic profiles of various leukemic cells.
    [Show full text]
  • Role of Ras/ERK-Dependent Pathway in the Erythroid Differentiation of K562 Cells
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 31, No 2, 76-82, June 1999 Role of Ras/ERK-dependent pathway in the erythroid differentiation of K562 cells Chi-Dug Kang1,2,5, In-Rok Do2, the elevated activity of ERK/MAPK to the level of Kwang-Woon Kim2, Byung-Kwon Ahn2, parental cells, the growth rate increased and the Sun-Hee Kim2, Byung-Seon Chung2, erythroid differentiation decreased slightly, and at Byung-Hak Jhun1,3 and Mi-Ae Yoo1,4 high concentration of PD98059, which inhibited the elevated activity of ERK/MAPK below that of the 1 Pusan Cancer Research Center, Pusan National University, Pusan 602-739, Korea parental cells, the growth rate turned down and the 2 Department of Biochemistry, College of Medicine, Pusan National University, Pusan erythroid differentiation was restored to the untreated 602-739, Korea control level. Taken together, these results suggest 3 Department of Pharmacy, College of Pharmacy, Pusan National University, Pusan that an appropriate activity of ERK/MAPK is required 609-735, Korea to maintain the rapid growth and transformed pheno- 4 Department of Molecular Biology, College of Natural Science, Pusan National type of K562 cells. University, Pusan 609-735, Korea 5 Corresponding author: Tel, +82-51-240-7739; Fax, +82-51-248-1118, E-mail, Keywords: K562, erythroid differentiation, Ras/ERK [email protected] pathway, PD98059 Accepted 17 May 1999 Introduction Abbreviations: CML, Chronic myelogenic leukemia; PTK, protein tyrosine kinase; The K562 cell line was established from pleural effusion MAPK/ERK-activating kinase, MEK; ERK, extracellular signal-regulated kinase; MAPK, of a patient with chronic myelogenous leukemia (CML) mitogen-activating kinase; SDS, sodium-dodecyl sulfate; PAGE, polyacrylamide gel- in blast crisis (Lozzio and Lozzio, 1975).
    [Show full text]
  • Megakaryocytic Differentiation of K562 Cells Is Associated with Changes
    [CANCER RESEARCH 50, 6323-6329. October 1. I990| Megakaryocytic Differentiation of K562 Cells Is Associated with Changes in the Cytoskeletal Organization and the Pattern of Chromatographically Distinct Forms of Phosphotyrosyl-specific Protein Phosphatases T. Martin Butler,1 Andrew Ziemiecki, and Robert R. Friis2 Institute for Clinical and Experimental Cancer Research, University of Bern, Tiefenaustrasse 120, CH-3004 Bern, Switzerland ABSTRACT entiation along an erythroid lineage. Herbimycin A, an inhibitor of protein phosphorylation, has been shown to induce differ We have analyzed morphological and biochemical changes occurring entiation of mouse embryonal carcinoma (F9), erythroleukemia during megakaryocytic differentiation of the human chronic myelogenous (MEL), and K562 cells (20, 21). Differentiation toward mega- leukemia cell line K562 induced by phorbol 12-myristate 13-acetate (I'M A). PMA-treated cells became growth arrested, were slightly larger karyocytes can be monitored by a reduction of growth potential and irregular in shape, adhered better to the culture flask surface, and (22), a reduction of expression of erythroid surface markers expressed the glycoprotein Ilia on their surfaces. The morphological (15), a reduction of c-myc expression (18, 23), an induction of changes induced by PMA treatment were associated with the disappear surface markers of the megakaryocytic lineage (15), an induc ance of actin from the cytosol and presumably reflect PMA-induced actin tion of c-sis and c-fos mRNA (23-25), and translocation of polymerization. Megakaryocytic differentiation was accompanied by protein kinase C from the cytoplasm to the membrane (22, 26). about a 3-fold decrease in the specific phosphotyrosine protein phospha- Erythroid differentiation is characterized by the induction of tase (PTPase) activity in the particulate membrane fraction, whereas the globin synthesis and the accumulation of hemoglobin together activity in the soluble cytosol fraction increased about 3-fold.
    [Show full text]
  • Induction of Differentiation of the Acute Myeloid Leukemia Cell Line (HL-60) by a Securinine Dimer Wen Hou1, Zhen-Ya Wang1, Jing Lin1 and Wei-Min Chen 1
    Hou et al. Cell Death Discovery (2020) 6:123 https://doi.org/10.1038/s41420-020-00354-3 Cell Death Discovery ARTICLE Open Access Induction of differentiation of the acute myeloid leukemia cell line (HL-60) by a securinine dimer Wen Hou1, Zhen-Ya Wang1, Jing Lin1 and Wei-Min Chen 1 Abstract Differentiation therapy has been successfully applied clinically in cases of acute promyelocytic leukemia (APL), but few differentiation-induction agents other than all-trans retinoic acid (ATRA) have been discovered clinically. Based on our previously reported neuritogenic differentiation activity of synthetic dimeric derivatives of securinine, we explored the leukemia differentiation-induction activity of such as compound, SN3-L6. It was found that SN3-L6 induces transdifferentiation of both acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML) cells but unexpectedly, a new transdifferentiation pathway from APL cells to morphologically and immunologically normal megakaryocytes and platelets were discovered. SN3-L6 fails to induce transdifferentiation of ATRA–produced mature granulocytes into megakaryocytes, indicating its selectivity between mature and immature cells. SN3-L6 induces CML K562 cells to transdifferentiate into apoptotic megakaryocytes but without platelet formation, indicating a desirable selectivity between different leukemia cells. Our data illuminate a differentiation gap between AML cells and platelets, and promises applications in leukemia differentiation therapy strategy. Introduction ATRA 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; differentiation-induction agents other than have Leukemia is characterized by a blockage of cell differ- since been discovered clinically. It is well known that entiation (Fig. 1). The most common method for treat- inducing APL cells to differentiate into mature granulo- ment of leukemia involves chemotherapeutic agents that cytes is the main pharmacologic action of ATRA.
    [Show full text]
  • Selective Induction of Apoptosis in Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Cells by an Inhibitor of BCR ± ABL Tyrosine Kinase, CGP 57148
    Cell Death and Differentiation (1998) 5, 710 ± 715 1998 Stockton Press All rights reserved 13509047/98 $12.00 http://www.stockton-press.co.uk/cdd Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR ± ABL tyrosine kinase, CGP 57148 Shingo Dan1, Mikihiko Naito1 and Takashi Tsuruo1,2,3 which is detected in virtually all cases. It is formed by a translocation between chromosome 9 and 22 (de Klein et al, 1 Institute of Molecular and Cellular Biosciences, The University of Tokyo, Tokyo 1982; Heisterkamp et al, 1983). This translocation results in a 2 Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, production of the BCR ± ABL fusion protein with enhanced Tokyo, Japan 3 tyrosine kinase activity, which is a major factor in the corresponding author: Institute of Molecular and Cellular Biosciences, The pathophysiology of CML (Heisterkamp et al, 1985; 1990). University of Tokyo, Yayoi, Bunkyo-ku, Tokyo 113, Japan. tel: 81-3-3818- 5341; fax: 81-3-3816-3592; e-mail: [email protected] The BCR ± ABL tyrosine kinase phosphorylates cellular proteins such as CRKL and CBL (Andoniou et al, 1994; Received 10.11.97; revised 6.3.98; accepted 2.4.98 Nichols et al, 1994; Oda et al, 1994). The phosphorylated Edited by: Y. Kuchino CRKL and CBL form a stable complex including BCR ± ABL and phosphatidylinositol-3' kinase (PI3K) (Sattler et al, 1996), which in turn activates PI3K to promote cell Abstract proliferation (Skorski et al, 1995). BCR ± ABL is also The BCR ± ABL tyrosine kinase has been implicated as the shown to activate Ras-dependent signaling pathways cause of Philadelphia chromosome (Ph1)-positive leukemias.
    [Show full text]
  • The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors
    Article The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia Erin Clapper 1,2, Giovanna Di Trapani 1,* and Kathryn F. Tonissen 1,2,* 1 School of Environment and Science, Griffith University, Nathan, QLD 4111, Australia; E.Clapper@griffith.edu.au 2 Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD 4111, Australia * Correspondence: G.DiTrapani@griffith.edu.au (G.D.T.); K.Tonissen@griffith.edu.au (K.F.T.) Abstract: Chronic myeloid leukemia (CML) is a myeloproliferative disorder that is caused by the formation of a fusion onco-protein, BCR-ABL. Since BCR-ABL plays a role in the progression of CML, the most common treatments of CML are tyrosine kinase inhibitors (TKIs) that specifically target BCR-ABL. However, resistance to TKIs is a major problem in CML treatment. A promising target in overcoming drug resistance in other cancers is the thioredoxin (TRX) system, an antioxidant system that maintains cellular redox homeostasis. The TRX system is upregulated in many cancers and this is associated with a poor prognosis. Analysis of a patient database showed that the expression of the TRX system was upregulated in CML patients compared to healthy donors. Our experiments revealed a significant link between the TRX and BCR-ABL systems since inhibition of BCR-ABL with chemical inhibitors and siRNA resulted in a decrease in the activity and expression of the TRX system in CML cells. This is notable as it shows that the TRX system may be a viable target in the treatment of CML. Citation: Clapper, E.; Di Trapani, G.; Keywords: chronic myeloid leukemia; BCR-ABL; thioredoxin; drug resistance; tyrosine kinase in- Tonissen, K.F.
    [Show full text]
  • Erythropoietin Promotes Resistance Against the Abl Tyrosine Kinase Inhibitor Imatinib (STI571) in K562 Human Leukemia Cells
    970 Vol. 1, 970–980, November 2003 Molecular Cancer Research Erythropoietin Promotes Resistance Against the Abl Tyrosine Kinase Inhibitor Imatinib (STI571) in K562 Human Leukemia Cells Karin M. Kirschner and Kurt Baltensperger Institute of Pharmacology, University of Bern, Bern, Switzerland Abstract malignant transformation of cells. Recent advances in the Chronic myeloid leukemia is characterized by the treatment of CML have largely relied on imatinib mesylate Philadelphia chromosome translocation that causes (STI571, Gleevec), a rationally designed inhibitor of the Abl expression of Bcr-Abl, a deregulated tyrosine kinase. tyrosine kinase (3). Imatinib potently suppresses the tyrosine Imatinib mesylate (STI571, Gleevec), a therapeutically kinase activity of the Bcr-Abl fusion protein and induces used inhibitor of Bcr-Abl, causes apoptosis of Bcr- apoptosis in Bcr-Abl-positive cells (4–9). The success of this Abl-positive cells. In the leukemia cell line K562, we novel drug is based on Bcr-Abl’s central place as the single observed spontaneous resistance to imatinib at very low most important component to maintain factor independence of frequencies when cells were exposed to the drug (1 MM) CML cells. The efficacy of imatinib in the treatment of chronic for more than 4 weeks. Surprisingly, in the presence of phase CML is well documented (8). Resistance resulting in erythropoietin (Epo), K562 cells were temporarily able to failure of treatment at initiation of therapy seems to be rare. sustain proliferation in the presence of imatinib, and However, several recent reports indicate that patients in the imatinib-resistant clones could be isolated with high accelerated phase and blast crisis that first responded well but frequencies.
    [Show full text]
  • And Imatinib-Resistant Chronic Myelogenous Leukemia Cells Seiichi Okabe, Tetsuzo Tauchi, and Kazuma Ohyashiki
    Cancer Therapy: Preclinical Characteristics of Dasatinib- and Imatinib-Resistant Chronic Myelogenous Leukemia Cells Seiichi Okabe, Tetsuzo Tauchi, and Kazuma Ohyashiki Abstract Purpose: Althoughdualsrc-familykinase/BCR/ABLinhibitor,dasatinib (BMS-354825),provides therapeutic advantages to imatinib-resistant cells, the mechanism of dasatinib resistance was not fully known. Experimental Design: We used TF-1 BCR/ABLcells, by introducing the BCR/ABL gene into a leukemia cell line,TF-1and K562, and established dasatinib- (BMS-R) and imatinib-resistant (IM-R) cells.We characterized chronic myelogenous leukemia drug-resistant cells and examined intracellular signaling. Results: The IC50 of dasatinib was 0.75 nmol/L(TF-1BCR/ABL), 1nmol/L(K562), 7.5 nmol/L (TF-1 BCR/ABLIM-R), 10 nmol/L(K562 IM-R), 15 Amol/L(TF-1 BCR/ABLBMS-R), and 25 Amol/L(K562 BMS-R).The number of BCR/ABLcopies in resistant cell lines was the same as the parental cell line by fluorescence in situ hybridization analysis. There was no mutation in Abl kinase.We found that protein levels of BCR/ABLwere reduced in dasatinib-resistant cell lines. BCR/ABLprotein was increased by treatment of an ubiquitin inhibitor.The Src kinase, Lck, as well as mitogen-activated protein kinase and Akt were activated, but p21WAF, phosphatase and tensin homologue was reduced in K562 BMS-R cells. Removal of dasatinib from the culture medium of K562 BMS-R cells led to apoptosis, and activated caspase 3 and poly (ADP-ribose) polymerase. Conclusion:These results suggest that the expression and protein activation signatures identified in this study provide insight into the mechanism of resistance to dasatinib and imatinib and may be of therapeutic chronic myelogenous leukemia value clinically.
    [Show full text]
  • Induction of Erythroid Differentiation in K562 Cells by Inhibitors of Inosine Monophosphate Dehydrogenase1
    [CANCER RESEARCH 49. 5555-5560. October 15. 1989] Induction of Erythroid Differentiation in K562 Cells by Inhibitors of Inosine Monophosphate Dehydrogenase1 John Yu,2 Victor Lemas, Theodore Page, James D. Connor, and Alice L. Yu Department of Molecular and Experimental Medicine, Research Institute of Scripps Clinic, La Jolla, California 92037 fj. Y., V. L.], and Department of Pediatrics, University of California at San Diego, La Jolla, California 92093 [T. P., J. D. C., A. L. Y. ] ABSTRACT by incubation with ribavirin were also analyzed. Preliminary reports of this investigation have been presented (15, 16). The effects of three inhibitors of inosine monophosphate (IMP) de- hydrogenase on a human erythroleukemic cell line, K562, were studied. Following incubation with these inhibitors, K562 cells underwent differ MATERIALS AND METHODS entiation and accumulated hemoglobins. The induction of hemoglobin accumulation was dose dependent; maximum induction was observed at Cell Culture. Stock cultures of K562 (American Type Culture Col 100, 25, and 3 MM,respectively, for ribavirin, tiazofurin, and mycophen- lection, Rockville, MD) were grown in RPMI 1640 medium supple olic acid. The induction was associated with reduction of intracellular mented with 50 lU/ml of penicillin, 50 Mg/ml of streptomycin, and GTP content and was blocked by adding guanosine within 24 h after 15% fetal calf serum (Hyclone Laboratories, Inc., Logan, UT), as adding inducer. The effective dose for half-maximum induction by riba previously described (17). Cells were caused to differentiate by addition virin was 3 times less than that for 50% inhibition of K562 proliferation; of inducers to final concentrations as specified in the text.
    [Show full text]
  • Induction of Terminal Differentiation in Human K562 Erythroleukemia Cells by Arabinofuranosylcytosine
    Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine. C Luisi-DeLuca, … , D Spriggs, D W Kufe J Clin Invest. 1984;74(3):821-827. https://doi.org/10.1172/JCI111498. Research Article We have previously demonstrated that continuous exposure of human HL-60 human promyelocytes to 1-beta-D- arabinofuranosylcytosine (ara-C) results in the induction of terminal differentiation to monocyte-like cells. The present study extends these findings by demonstrating that ara-C induces hemoglobin synthesis in human K562 erythroleukemia cells. This effect occurs maximally at an ara-C concentration (5 X 10(-7) M) that results in K562 cytostasis. In contrast to the reversible effects of hemin and hydroxyurea on globin synthesis in this cell line, we have found that the induction of K562 hemoglobin synthesis by ara-C is irreversible. An induction of K562 hemoglobin synthesis also occurs with aphidicolin, another inhibitor of S-phase DNA synthesis, but not with vinblastine, an inhibitor of mitosis. Finally, ara-C induction of a differentiated K562 phenotype is accompanied by the loss of self-renewal capacity, a finding consistent with terminal differentiation. Find the latest version: https://jci.me/111498/pdf Induction of Terminal Differentiation in Human K562 Erythroleukemia Cells by Arabinofuranosylcytosine Cynthia Luisi-DeLuca, Thomas Mitchell, David Spriggs, and Donald W. Kufe Division of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115 Abstract. We have previously demonstrated inhibition of replicative DNA synthesis by ara-C causes DNA that continuous exposure of human HL-60 human fragmentation (4). Furthermore, there is a highly significant promyelocytes to 1-fl-D-arabinofuranosylcytosine (ara- relationship between the incorporation of ara-C into DNA and C) results in the induction of terminal differentiation to the loss of leukemic cell clonogenic survival (2, 5, 6).
    [Show full text]
  • Detection of BCR-ABL Proteins in Blood Cells of Benign Phase Chronic Myelogenous Leukemia Patients1
    ICANCER RESEARCH 51. 3048-3051. June 1. 19911 Advances in Brief Detection of BCR-ABL Proteins in Blood Cells of Benign Phase Chronic Myelogenous Leukemia Patients1 Jie Qiang Guo, Jean Y. J. Wang, and Ralph B. Arlinghaus2 Department of Molecular Pathology, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030 fJ. Q. C., R. B. A.], and Department of Biology, The University of California at San Diego. La lolla, CA 92093 [J. Y. J. W.¡ Abstract protein in cell lines derived from blast crisis CML patients. The BCR-ABL protein kinase assay has also been used to detect More than 95% of patients with chronic myelogenous leukemia (CML) P210 BCR-ABL in uncultured cells from patients in blast crisis contain an abnormal chromosome termed the Philadelphia chromosome (Ph1). I'll1 and the resulting BCR-ABL fused genes are markers for this (13). Attempts to detect the BCR-ABL protein in chronic phase type of leukemia. The product of the fused BCR-ABL genes is a protein patients by this assay have been hindered by large numbers of of about 2000 amino acids termed P210 BCR-ABL. Although the BCR- mature cells in blood and bone marrow samples in these pa ABL protein can be routinely detected in blood cells from blast crisis tients, which contain high concentrations of degradative en CML patients by assaying for its activated tyrosine kinase activity, zymes (13). Extracts of mature granulocytes, from either nor detection of P210 BCR-ABL in early stage CML patients (chronic phase) mal or CML patients, rapidly destroy P210 kinase activity from has not yet been possible (S.
    [Show full text]